

Joseph Ciccolini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8010692/joseph-ciccolini-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148 papers	3,265 citations	33 h-index	50 g-index
159 ext. papers	3,892 ext. citations	4.9 avg, IF	5.3 L-index

#	Paper	IF	Citations
148	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
147	Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 565	3.5	
146	Detecting DPD deficiency: when perfect is the enemy of good. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 717-719	3.5	0
145	Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. <i>Cancer Medicine</i> , 2021 , 10, 2250-2258	4.8	1
144	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00757	3.1	4
143	Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
142	COVID-19 vaccine race: watch your step for cancer patients. <i>British Journal of Cancer</i> , 2021 , 124, 860-861	8.7	15
141	The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?. <i>Translational Oncology</i> , 2021 , 14, 100952	4.9	
140	Mechanistic models for hematological toxicities: Small is beautiful. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 396-398	4.5	0
139	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
138	Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. <i>Journal of Controlled Release</i> , 2021 , 338, 244-252	11.7	2
137	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. <i>Vaccines</i> , 2020 , 8,	5.3	7
136	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. <i>JCO Precision Oncology</i> , 2020 , 4, 486-491	3.6	4
135	Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeer meets QUANTIC. <i>British Journal of Cancer</i> , 2020 , 123, 337-338	8.7	3
134	Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 458-470	6.1	8
133	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. <i>PLoS Computational Biology</i> , 2020 , 16, e1007178	5	30
132	A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer. <i>Clinical and Translational Science</i> , 2020 , 13, 761-768	4.9	5

131	A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1138, 121968	3.2	5
130	Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. <i>Pharmacogenomics</i> , 2020 , 21, 173-179	2.6	2
129	Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). <i>Anti-Cancer Drugs</i> , 2020 , 31, 463-472	2.4	5
128	All You Need to Know About Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2020 , 16, 793-798	2.3	21
127	Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. <i>Pharmaceutics</i> , 2020 , 12,	6.4	7
126	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020 , 12,	6.4	4
125	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
124	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
123	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
122	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
121	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
120	Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors 2020 , 16, e1007178		
119	Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropyrimidine dehydrogenase deficiency. <i>Pharmacogenomics</i> , 2019 , 20, 931-938	2.6	5
118	Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1126-1127, 121770	3.2	4
117	Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 577-586	4.5	4
116	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1213-1214	3.8	3
115	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. <i>Anticancer Research</i> , 2019 , 39, 3419-3422	2.3	4
114	Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor. <i>Lecture Notes in Computer Science</i> , 2019 , 87-97	0.9	1

113	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 835-857	6.2	111
112	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 142-159	3.2	4
111	Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 66-74	3.2	2
110	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. <i>European Respiratory Review</i> , 2018 , 27,	9.8	14
109	Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. <i>International Journal of Nanomedicine</i> , 2018 , 13, 3451-3465	7.3	28
108	Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 1-12	7	28
107	Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 42-50	4.5	9
106	Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1139-1147	5.5	14
105	From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. <i>International Journal of Nanomedicine</i> , 2018 , 13, 6677-6688	7.3	19
104	CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. <i>Blood Advances</i> , 2018 , 2, 462-469	7.8	12
103	Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 599-610	3.8	11
102	Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 290-296	3.2	2
101	PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1265-1266	3.5	1
100	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. <i>Clinical Cancer Research</i> , 2017 , 23, 7171-7179 ¹¹	12.9	11
99	A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. <i>Scientific Reports</i> , 2017 , 7, 2714	4.9	32
98	Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. <i>Seminars in Oncology</i> , 2017 , 44, 159-160	5.5	4
97	Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy. <i>Cancer Research</i> , 2017 , 77, 4723-4733	10.1	27
96	Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. <i>Oncotarget</i> , 2017 , 8, 23087-23098	3.3	22

95	Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. <i>Oncotarget</i> , 2017 , 8, 47161-47166	3.3	17
94	UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS. <i>Clinical Cancer Drugs</i> , 2017 , 4, 122-128	0.2	12
93	Pharmacokinetics and Pharmacogenetics of Metronomics 2016 , 189-207		
92	Women at a Disadvantage in Fluorouracil Treatment. <i>JAMA Oncology</i> , 2016 , 2, 829-30	13.4	5
91	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. <i>Biomarker Insights</i> , 2016 , 11, 105-11	3.5	15
90	A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. <i>BMC Cancer</i> , 2016 , 16, 278	4.8	18
89	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. <i>Cancer Research</i> , 2016 , 76, 4931-40	10.1	84
88	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 759-69	5.4	6
87	Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1015-25	6.2	16
86	Computational oncology--mathematical modelling of drug regimens for precision medicine. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 242-54	19.4	133
85	Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations. <i>Anticancer Research</i> , 2016 , 36, 6051-6057	2.3	13
84	In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling. <i>Scientific Reports</i> , 2016 , 6, 36173	4.9	14
83	Nucleoside analogs: ready to enter the era of precision medicine?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 865-77	5.5	5
82	An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. <i>British Journal of Radiology</i> , 2016 , 89, 20160061	3.4	2
81	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1-12	3.5	99
80	Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 124-30	3.8	33
79	Pharmacogenetics and breast cancer management: current status and perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 719-29	5.5	9
78	Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E3453	11.5	8

77	Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report. <i>Pharmacogenomics</i> , 2015 , 16, 677-9	2.6	4
76	Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter. <i>Clinical Cancer Research</i> , 2015 , 21, 934	12.9	
75	DPD deficiency in patients treated with fluorouracil. <i>Lancet Oncology, The</i> , 2015 , 16, 1574-6	21.7	9
74	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. <i>Seminars in Cancer Biology</i> , 2015 , 35, 53-61	12.7	50
73	Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. <i>Pharmacogenomics</i> , 2015 , 16, 1907-12	2.6	9
72	Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 665-72	5.5	45
71	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. <i>PLoS ONE</i> , 2015 , 10, e0135907	3.7	12
70	Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 317-21	1.9	5
69	Biodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size matters. <i>Pharmaceutical Research</i> , 2014 , 31, 2677-84	4.5	19
68	Metronomics chemotherapy: time for computational decision support. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 647-52	3.5	30
67	Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014 , 33, 403-12	12.4	14
66	Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice. <i>Cancer Research</i> , 2014 , 74, 6397-407	10.1	71
65	Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 527-9	1.9	3
64	Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models 2014 ,		3
63	Trastuzumab-induced cardiotoxicity: is it a personalized risk?. <i>Current Drug Targets</i> , 2014 , 15, 1200-4	3	7
62	Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 504-13	7	74
61	Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. <i>Pharmacogenomics</i> , 2013 , 14, 1047-51	2.6	32
60	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013 , 14, 931-9	2.6	36

59	In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity. <i>Pharmaceutical Research</i> , 2013 , 30, 1281-90	4.5	11
58	Optimization of trans-Resveratrol bioavailability for human therapy. <i>Biochimie</i> , 2013 , 95, 1233-8	4.6	67
57	Gender, cytidine deaminase, and 5-aza/decitabine--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 3105	12.9	8
56	Research Highlights: Highlights from the latest articles in pharmacogenomics. <i>Pharmacogenomics</i> , 2013 , 14, 1137-1139	2.6	
55	A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. <i>Comptes Rendus Mathematique</i> , 2012 , 350, 23-28	0.4	16
54	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2063-5	1.9	4
53	Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 530-7	3.1	9
52	La pharmacogénétique constitutionnelle est-elle le chaînon manquant de la médecine personnalisée en oncologie ?. <i>Bulletin Du Cancer</i> , 2012 , 99, 903-905	2.4	
51	A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 317	12.9	6
50	Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. <i>Journal of Clinical Oncology</i> , 2012 , 30, e41-4	2.2	22
49	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. <i>Pharmacogenomics</i> , 2012 , 13, 393-7	2.6	15
48	Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. <i>ISRN Pharmaceuticals</i> , 2012 , 2012, 738432		36
47	Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1713-9	3	11
46	100% human monoclonal antibodies in oncology: hype or breakthrough?. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1643-8	3	1
45	DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 49-56	3.5	58
44	5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 823-6	3.5	25
43	Integrating pharmacogenetics into gemcitabine dosing--time for a change?. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 439-44	19.4	53
42	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. <i>Oncotarget</i> , 2011 , 2, 797-809	3.3	154

41	Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. <i>Journal of Clinical Oncology</i> , 2010 , 28, 160-5	2.2	94
40	Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 224-8	3.8	66
39	Reply to E. Giovannetti et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e223-e225	2.2	4
38	High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 53-60	3.2	16
37	Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 959-60	2.8	7
36	Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?. <i>Pediatric Blood and Cancer</i> , 2010 , 54, 781-2	3	4
35	Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. <i>PLoS ONE</i> , 2009 , 4, e4409	3.7	57
34	Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?. <i>Current Medicinal Chemistry</i> , 2009 , 16, 4361-71	4.3	66
33	Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 1177-80	3.5	34
32	A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 966-70	3.8	9
31	Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines. <i>Planta Medica</i> , 2008 , 74, 1265-8	3.1	13
30	High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. <i>Anti-Cancer Drugs</i> , 2008 , 19, 267-73	2.4	36
29	Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. <i>Phytotherapy Research</i> , 2008 , 22, 1299-302	6.7	16
28	Validation of a simple HPLC method for assay of haplamine and its metabolites in plasma suitable for pharmacokinetic application in rats. <i>Biomedical Chromatography</i> , 2008 , 22, 125-30	1.7	6
27	Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer 2008 , 249-265		
26	Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4855; author reply 4855-6	2.2	15
25	Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 841-4	1.9	45
24	Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 597-8	13.2	27

23	Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 272-5	3.5	38
22	Pharmacogenetics of capecitabine in advanced breast cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 5496-502	12.9	91
21	Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 288-96	3.8	57
20	Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 532-9	3.2	28
19	Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. <i>Anti-Cancer Drugs</i> , 2006 , 17, 463-70	2.4	11
18	A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 678-85	3.2	73
17	Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5-deoxyuridine. <i>Anti-Cancer Drugs</i> , 2006 , 17, 807-13	2.4	4
16	Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 212-8	3.2	19
15	Taxotere-5-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. <i>Anti-Cancer Drugs</i> , 2005 , 16, 309-16	2.4	7
14	Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. <i>Anti-Cancer Drugs</i> , 2005 , 16, 675-82	2.4	5
13	Development of stealth liposome formulation of 2-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. <i>Pharmaceutical Research</i> , 2005 , 22, 2051-7	4.5	16
12	Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1962-71	6.1	23
11	Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2004 , 4, 71-81		34
10	A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004 , 29, 307-15	2.2	65
9	Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5-deoxy-5-fluorouridine on human keratinocytes. <i>Anti-Cancer Drugs</i> , 2004 , 15, 969-74	2.4	20
8	Molecular mechanisms underlying the interaction between ZD1839 (Iressa) and cisplatin/5-fluorouracil. <i>British Journal of Cancer</i> , 2003 , 89, 585-92	8.7	69
7	Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 102-8	12.9	8
6	ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. <i>Clinical Cancer Research</i> , 2003 , 9, 4735-42	12.9	35

5	Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. <i>Biochemical Pharmacology</i> , 2002 , 63, 1831-42	6	55
4	Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 709-14	3.2	18
3	Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 923-7	6.1	15
2	Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. <i>Fundamental and Clinical Pharmacology</i> , 2000 , 14, 147-54	3.1	12
1	Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. <i>British Journal of Cancer</i> , 1999 , 80, 1726-33	8.7	73